Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia

Bone Marrow Transplantation volume 46, pages 34–43 (2011)Cite this article

Subjects

Abstract

We retrospectively compared clinical outcomes in 1593 T-replete unrelated donor (URD) marrow transplant recipients with AML, MDS and CML who received myeloablative conditioning regimens of either BU and CY (BuCy), standard-dose Cy/TBI (1000–1260 cGy) or high-dose Cy/TBI (1320–1500 cGy). Subjects were drawn from patients transplanted between 1991 and 1999 facilitated by the National Marrow Donor Program. Patients who received high-dose Cy/TBI regimens were slightly younger, more likely to receive a mismatched transplant and to have intermediate or advanced disease compared with patients in the BuCy or standard-dose TBI group. Neutrophil recovery was significantly higher in the standard-dose CY/TBI group compared with the high-dose Cy/TBI or BuCy group. Patients who received the high-dose Cy/TBI regimen had an increased risk of developing grades III–IV aGVHD when compared with the control group who received BuCy (P=0.011). OS, disease-free survival (DFS), TRM and relapse were not significantly different between any of the regimens. We conclude that BuCy, standard-dose and high-dose Cy/TBI regimens have equivalent efficacy profiles for OS, DFS, TRM and relapse risk in patients undergoing T-replete URD marrow transplantation for AML, CML and MDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.

    Article  CAS  Google Scholar 

  2. Van der Jagt RH, Appelbaum FR, Petersen FB, Bigelow CL, Fisher LD, Schoch GH et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211–215.

    CAS  PubMed  Google Scholar 

  3. Bertz H, Potthoff K, Mertelsmann R, Finke J . Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169–1173.

    Article  CAS  Google Scholar 

  4. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578–2582.

    CAS  PubMed  Google Scholar 

  5. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.

    CAS  PubMed  Google Scholar 

  6. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.

    CAS  PubMed  Google Scholar 

  7. Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960–3962.

    CAS  PubMed  Google Scholar 

  8. Klein JL, Avalos BR, Belt P, Taylor CA, Ezzone SA, Scholl MD et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17: 479–483.

    CAS  PubMed  Google Scholar 

  9. Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplant 1996; 17: 685–689.

    CAS  PubMed  Google Scholar 

  10. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12: 876–884.

    Article  CAS  Google Scholar 

  11. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748–758.

    Article  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  13. Kaplan E . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  14. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  Google Scholar 

  15. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  16. Santos GW . Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Ann N Y Acad Sci 1995; 770: 1–7.

    Article  CAS  Google Scholar 

  17. Ferrebee JW, Thomas ED . Radiation injury and marrow replacement: factors affecting survival of the host and the homograft. Ann Intern Med 1958; 49: 987–1003.

    Article  CAS  Google Scholar 

  18. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

    Article  CAS  Google Scholar 

  19. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.

    CAS  PubMed  Google Scholar 

  20. Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 1993; 20: 33–38;quiz 39.

    CAS  PubMed  Google Scholar 

  21. Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187–2193.

    CAS  PubMed  Google Scholar 

  22. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263–2268.

    CAS  PubMed  Google Scholar 

  23. Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119: 1115–1124.

    Article  CAS  Google Scholar 

  24. Hartman AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439–443.

    Article  CAS  Google Scholar 

  25. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.

    Article  CAS  Google Scholar 

  26. Ferrara JL, Levy R, Chao NJ . Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347–356.

    Article  CAS  Google Scholar 

  27. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    CAS  PubMed  Google Scholar 

  28. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  29. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.

    CAS  PubMed  Google Scholar 

  30. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201–1207.

    Article  CAS  Google Scholar 

  31. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944–950.

    Article  CAS  Google Scholar 

  32. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196–2201.

    CAS  PubMed  Google Scholar 

  33. Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA et al. Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 2004; 173: 2050–2059.

    Article  CAS  Google Scholar 

  34. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977–1983.

    Article  CAS  Google Scholar 

  35. Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18–25; quiz 26.

    CAS  PubMed  Google Scholar 

  36. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93: 4436–4440.

    CAS  PubMed  Google Scholar 

  37. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493–500.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge Esteban M Abella, MD, Asad Bashey, MD, PhD, Scott I Bearman, MD, Arkadiusz Dudek, MD, PhD, FACP, Stephanie Elkins, MD, Nancy A. Kernan, MD and James Wade, MD for their contributions to this manuscript. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Aetna; American Society for Blood and Marrow Transplantation; Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Association of Medical Microbiology and Infectious Disease Canada; Astellas Pharma US Inc.; Baxter International Inc.; Bayer HealthCare Pharmaceuticals; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Canadian Blood and Marrow Transplant Group; Celgene Corporation; CellGenix GmbH; Centers for Disease Control and Prevention; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Cubist Pharmaceuticals; Cylex Inc.; CytoTherm; DOR BioPharma Inc.; Dynal Biotech, an Invitrogen Company; Enzon Pharmaceuticals Inc.; European Group for Blood and Marrow Transplantation; Gambro BCT Inc.; Gamida Cell Ltd; Genzyme Corporation; Histogenetics Inc.; HKS Medical Information Systems; Hospira Inc.; Infectious Diseases Society of America; Kiadis Pharma; Kirin Brewery Co., Ltd; Merck & Company; The Medical College of Wisconsin; MGI Pharma Inc.; Michigan Community Blood Centers; Millennium Pharmaceuticals Inc.; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec Inc.; National Marrow Donor Program; Nature Publishing Group; New York Blood Center; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics Inc.; Otsuka Pharmaceutical Development & Commercialization Inc.; Pall Life Sciences; PDL BioPharma Inc.; Pfizer Inc.; Pharmion Corporation; Saladax Biomedical Inc.; Schering Plough Corporation; Society for Healthcare Epidemiology of America; StemCyte Inc.; StemSoft Software Inc.; Sysmex; Teva Pharmaceutical Industries; The Marrow Foundation; THERAKOS Inc.; Vidacare Corporation; Vion Pharmaceuticals Inc.; ViraCor Laboratories; ViroPharma Inc.; and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense or any other agency of the US Government.

Author information

Authors and Affiliations

  1. Wayne State University Karmanos Cancer Center, Detroit, MI, USA

    J P Uberti & V Ratanatharathorn

  2. Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    M-A Agovi, S Tarima & J D Rizzo

  3. Medical College of Wisconsin, Milwaukee, WI, USA

    M-A Agovi, S Tarima & J D Rizzo

  4. Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA

    M Haagenson

  5. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    S Gandham & K S Baker

  6. H. Lee Moffitt Cancer Center and Research, Tampa, FL, USA

    C Anasetti

  7. Cleveland Clinic Foundation, Cleveland, OH, USA

    B J Bolwell & E Copelan

  8. Universitatsklinikum Carl Gustav Carus, Dresden, Germany

    M Bornhauser

  9. Texas Transplant Institute, San Antonio, TX, USA

    K W Chan

  10. Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA

    S M Davies

  11. Freiburg University Medical Center, Freiburg, Germany

    J Finke

  12. All Children's Hospital, St Petersburg, FL, USA

    G A Hale

  13. Jaeb Center for Health Research, Tampa, FL, USA

    C Kollman

  14. Roswell Park Cancer Institute, Buffalo, NY, USA

    P L McCarthy

  15. Karolinska Institutet, Stockholm, Sweden

    O Ringdén

  16. University of Minnesota Medical Center, Minneapolis, MN, USA

    D J Weisdorf

Authors
  1. J P Uberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-A Agovi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Tarima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Haagenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Gandham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Anasetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K S Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B J Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Bornhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K W Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S M Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G A Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C Kollman
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. P L McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. V Ratanatharathorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. O Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. D J Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J D Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J P Uberti.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uberti, J., Agovi, MA., Tarima, S. et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 46, 34–43 (2011). https://doi.org/10.1038/bmt.2010.81

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.81

Keywords

This article is cited by

Search

Advanced search

Quick links